Item Type | Name |
Concept
|
Age Factors
|
Concept
|
Chromosomes, Human, Pair 5
|
Concept
|
Chromosomes, Human, Pair 6
|
Concept
|
Chromosomes, Human, Pair 9
|
Concept
|
Colony-Stimulating Factors
|
Concept
|
Humans
|
Concept
|
Risk Factors
|
Concept
|
Sex Factors
|
Concept
|
Time Factors
|
Concept
|
Transcription Factors
|
Concept
|
Core Binding Factors
|
Concept
|
Basic-Leucine Zipper Transcription Factors
|
Concept
|
Erythroid-Specific DNA-Binding Factors
|
Concept
|
Kruppel-Like Transcription Factors
|
Concept
|
MEF2 Transcription Factors
|
Academic Article
|
Neuropsychologic (cognitive) disabilities in long-term survivors of childhood cancer.
|
Academic Article
|
Disseminated infection with Fusarium in recipients of bone marrow transplants.
|
Academic Article
|
Diffuse bony metastases at presentation in a child with glioblastoma multiforme. A case report.
|
Academic Article
|
Bilirubinuria: an early indicator of gallbladder hydrops associated with Kawasaki disease.
|
Academic Article
|
Nitrous oxide analgesia in a pediatric emergency department.
|
Academic Article
|
Acute acetone intoxication in a pediatric patient.
|
Academic Article
|
Oral care with vancomycin paste for reduction in incidence of alpha-hemolytic streptococcal sepsis.
|
Academic Article
|
Unrelated-donor bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in children.
|
Academic Article
|
Adenocarcinoma of minor salivary gland origin with skeletal metastasis in a child.
|
Academic Article
|
Use of DNA polymorphisms to monitor engraftment after allogeneic bone marrow transplantation.
|
Academic Article
|
Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's cancer group study CCG-2891.
|
Academic Article
|
Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): a phase I study of the Pediatric Blood and Marrow Transplant Consortium.
|
Academic Article
|
Transient myeloproliferative disorder, a disorder with too few data and many unanswered questions: does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia?
|
Academic Article
|
Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.
|
Academic Article
|
Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
|
Academic Article
|
Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
|
Academic Article
|
Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
|
Academic Article
|
Surveys: a tool to provoke thought and identify areas of need.
|
Academic Article
|
Acute myeloid leukemia and Down syndrome evolution of modern therapy--state of the art review.
|
Academic Article
|
Exposure to medical test irradiation and acute leukemia among children with Down syndrome: a report from the Children's Oncology Group.
|
Academic Article
|
Analysis of JAK3, JAK2, and C-MPL mutations in transient myeloproliferative disorder and myeloid leukemia of Down syndrome blasts in children with Down syndrome.
|
Academic Article
|
Vitamin supplement use among children with Down's syndrome and risk of leukaemia: a Children's Oncology Group (COG) study.
|
Academic Article
|
Respiratory syncytial virus infections in children with acute myeloid leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
Congenital abnormalities and acute leukemia among children with Down syndrome: a Children's Oncology Group study.
|
Academic Article
|
Hematopoietic colony-stimulating factor priming does not influence survival in acute myeloid leukemia: a meta-analysis of randomized trials.
|
Academic Article
|
Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia.
|
Academic Article
|
Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia.
|
Academic Article
|
International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia.
|
Academic Article
|
Successful mobilization with AMD3100 and filgrastim with engraftment of autologous peripheral blood stem cells in a heavily pretreated pediatric patient with recurrent Burkitt lymphoma.
|
Academic Article
|
Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.
|
Academic Article
|
High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group.
|
Academic Article
|
Allogeneic marrow transplantation in children with acute leukemia: careful comparison with chemotherapy alternatives required.
|
Academic Article
|
Differentiating between congenital rhabdomyosarcoma versus fibromatosis of the pediatric tongue.
|
Academic Article
|
Bowel obstruction after treatment of intra-abdominal tumors.
|
Academic Article
|
Prognostic factors in pediatric acute myeloid leukemia.
|
Academic Article
|
WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group.
|
Academic Article
|
Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group.
|
Academic Article
|
Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group.
|
Academic Article
|
A phase II study of amifostine in children with myelodysplastic syndrome: a report from the Children's Oncology Group study (AAML0121).
|
Academic Article
|
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.
|
Academic Article
|
Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG.
|
Academic Article
|
Life-threatening and fatal infections in children with acute myeloid leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
FLT3 mutation status is a predictor of early death in pediatric acute promyelocytic leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.
|
Academic Article
|
Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
|
Academic Article
|
Merging of the National Cancer Institute-funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group.
|
Academic Article
|
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.
|
Academic Article
|
High expression of neutrophil elastase predicts improved survival in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
Identification of regulators of polyploidization presents therapeutic targets for treatment of AMKL.
|
Academic Article
|
Transient myeloproliferative disorder in children with Down syndrome: clarity to this enigmatic disorder.
|
Academic Article
|
Relationship between pediatric blood and marrow transplant center volume and day +100 mortality: Pediatric Blood and Marrow Transplant Consortium experience.
|
Academic Article
|
Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemia.
|
Academic Article
|
Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.
|
Academic Article
|
Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy.
|
Academic Article
|
Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.
|
Academic Article
|
Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group.
|
Academic Article
|
Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: a report from the Children's Oncology Group.
|
Academic Article
|
Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.
|
Academic Article
|
The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group.
|
Academic Article
|
Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes.
|
Academic Article
|
Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group.
|
Academic Article
|
Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group.
|
Academic Article
|
BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
Gene expression profiling to predict viridans group streptococcal and invasive fungal infection in pediatric acute myeloid leukemia: a brief report from the Children's Oncology Group.
|
Academic Article
|
Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.
|
Academic Article
|
High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.
|
Academic Article
|
AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia.
|
Academic Article
|
A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children?s Oncology Group trial AAML0531.
|
Academic Article
|
NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.
|
Academic Article
|
Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report.
|
Academic Article
|
Immune-related conditions and acute leukemia in children with Down syndrome: a Children's Oncology Group report.
|
Academic Article
|
Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group.
|
Academic Article
|
Earlier initiation of antibiotic therapy: Does prophylaxis offer greater benefit in AML?
|
Academic Article
|
Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
|
Academic Article
|
Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group.
|
Academic Article
|
Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group.
|
Academic Article
|
Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group.
|
Academic Article
|
Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group.
|
Academic Article
|
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
|
Academic Article
|
A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.
|
Academic Article
|
Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia.
|
Academic Article
|
Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse.
|
Academic Article
|
A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group.
|
Academic Article
|
CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.
|
Academic Article
|
Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group.
|
Academic Article
|
Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group.
|
Academic Article
|
Early discharge as a mediator of greater ICU-level care requirements in patients not enrolled on the AAML0531 clinical trial: a Children's Oncology Group report.
|
Academic Article
|
miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.
|
Academic Article
|
Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia.
|
Academic Article
|
Health-related Quality of Life (HR-QOL) and Chronic Health Conditions in Survivors of Childhood Acute Myeloid Leukemia (AML) with Down Syndrome (DS): A Report From the Children's Oncology Group.
|
Academic Article
|
Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
|
Academic Article
|
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
|
Academic Article
|
Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
|
Academic Article
|
Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group.
|
Academic Article
|
Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
|
Academic Article
|
CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
|
Academic Article
|
Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531.
|
Academic Article
|
Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.
|
Academic Article
|
Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531.
|
Academic Article
|
MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia.
|
Academic Article
|
The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions.
|
Academic Article
|
CD33 splicing SNP regulates expression levels of CD33 in normal regenerating monocytes in AML patients.
|
Academic Article
|
Risk Markers for Significant Bleeding and Thrombosis in Pediatric Acute Promyelocytic Leukemia; Report From the Children's Oncology Group Study AAML0631.
|
Academic Article
|
Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia.
|
Academic Article
|
Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group.
|
Academic Article
|
ABCB1 SNP predicts outcome in patients with acute myeloid leukemia treated with Gemtuzumab ozogamicin: a report from Children's Oncology Group AAML0531 Trial.
|
Academic Article
|
Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia.
|
Academic Article
|
Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.
|
Academic Article
|
Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431.
|
Academic Article
|
Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group.
|
Academic Article
|
Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force.
|
Academic Article
|
Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study.
|
Academic Article
|
Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib.
|
Academic Article
|
Overcoming Wnt-?-catenin dependent anticancer therapy resistance in leukaemia stem cells.
|
Academic Article
|
Effect of Dexrazoxane on Left Ventricular Systolic Function and Treatment Outcomes in Patients With Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
|
Academic Article
|
Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report.
|
Academic Article
|
Morphologic remission status is limited compared to ?N flow cytometry: a Children's Oncology Group AAML0531 report.
|
Academic Article
|
Acute erythroid leukemia is enriched in NUP98 fusions: a report from the Children's Oncology Group.
|
Academic Article
|
MYOD1 as a prognostic indicator in rhabdomyosarcoma.
|
Academic Article
|
Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia.
|
Academic Article
|
CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group.
|
Academic Article
|
Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531.
|
Academic Article
|
High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial.
|
Academic Article
|
Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group.
|
Academic Article
|
CBFB-MYH11 fusion transcripts distinguish acute myeloid leukemias with distinct molecular landscapes and outcomes.
|
Academic Article
|
Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group.
|
Academic Article
|
Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF-?B subunit RelA.
|
Academic Article
|
Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial.
|
Academic Article
|
Polygenic Ara-C Response Score Identifies Pediatric Patients With Acute Myeloid Leukemia in Need of Chemotherapy Augmentation.
|
Academic Article
|
Adolescent and young adult (AYA) versus pediatric patients with acute leukemia have a significantly increased risk of acute GVHD following unrelated donor (URD) stem cell transplantation (SCT): the Children's Oncology Group experience.
|
Academic Article
|
Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children's Oncology Group study.
|
Academic Article
|
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031.
|
Academic Article
|
A ten-gene DNA-damage response pathway gene expression signature predicts gemtuzumab ozogamicin response in pediatric AML patients treated on COGAAML0531 and AAML03P1 trials.
|
Academic Article
|
Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy.
|
Academic Article
|
Integrated stem cell signature and cytomolecular risk determination in pediatric acute myeloid leukemia.
|
Academic Article
|
Pathologic, cytogenetic, and molecular features of acute myeloid leukemia with megakaryocytic differentiation: A report from the Children's Oncology Group.
|
Academic Article
|
Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia.
|
Academic Article
|
Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia.
|
Academic Article
|
Characteristics and prognostic impact of IDH mutations in AML: a?COG, SWOG, and ECOG analysis.
|
Academic Article
|
Valosin-containing protein (VCP/p97) is prognostically unfavorable in pediatric AML, and negatively correlates with unfolded protein response proteins IRE1 and GRP78: A report from the Children's Oncology Group.
|